Navigation Links
Solid tumor cells not killed by radiation and chemotherapy become stronger
Date:6/9/2008

tumors. In fact, however, oxygen levels cycle up and down virtually everywhere in the tumor, which is caused by fluctuations in blood flow rate. It has been a challenge to convince people of this."

Dewhirst and colleagues have made movies of oxygen transport in a tumor of a living animal that show the oxygen levels cycle up and down significantly, pulsing in waves seen as color changes in the movies. (View these movies at the Nature Reviews Cancer site: http://www.nature.com/nrc/journal/v8/n6/suppinfo/nrc2397.html )

The Duke team argues that blocking HIF1 is the consistent answer to tumor growth problems. Blocking HIF1 activity interferes with the tumor's ability to undergo glycolysis (energy production) in low-oxygen conditions, which blocks tumor growth, the authors wrote. Exactly how to accomplish chemotherapy or radiation treatment in the safest, most effective ways, in combination with HIF1 blockade, is still open for exploration, Dewhirst said.

For example, targeting HIF1 in the early stages of tumor growth, especially in very early cancer spread, may help, Dewhirst said. "For a woman who has had a primary breast tumor removed, and who is at high risk for cancer spread, this might be a situation in which you'd target HIF1," he explained. "Blocking HIF1 makes sense during the early stages of angiogenesis, which is the accelerated phase of blood vessel formation. In this way, you could keep the early metastasis sites inactive and prevent them from growing."

The Duke team has completed a phase I trial with a HIF1 inhibitor. "We are actively pursuing this clinically and will be moving this study into Phase 2," Dewhirst said. "We are interested in other applications of HIF-1 inhibition in combination with radiation and chemotherapy for different diseases."


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. MedAmerica Reports Solid Growth, Outperforms Industry
2. Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark
3. STAAR Surgical Reports Solid First Quarter Progress
4. Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
5. A long-term survival offered by resection of solid-pseudopapillary tumor of the pancreas?
6. New target for cancer therapy may improve treatment for solid tumors
7. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
8. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
9. SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services
10. Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross
11. James E. Harris to Become Chief Financial Officer of Coca-Cola Bottling Co. Consolidated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Boston, MA (PRWEB) September 02, 2014 ... normal for everyone. But sometimes the onset of irritability, ... serious condition, reports the September 2014 Harvard Health ... in response to everyday stresses. If they occur for ... functioning, it's an indication to seek help," says Dr. ...
(Date:9/2/2014)... The global market for peripheral vascular ... 2020, growing at an estimated CAGR of 7.2% from ... Grand View Research, Inc. Peripheral vascular devices such as ... used for treating peripheral arterial or coronary arterial diseases ... arteries. These devices are used to decrease the interference ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Researchers in New ... who developed mesothelioma after being exposed to asbestos-contaminated work clothes ... all the details of the report in a new article. ... at the ESI Model Hospital say their patient was ... breathlessness. Further investigation found that she had come in contact ...
(Date:9/2/2014)... Colo. (PRWEB) September 02, 2014 MyRounding, ... patient care, has been selected from a group of ... of the 2014 PrIME Digital Health Challenge. The competition ... one another, Tuesday, Sept. 9th at the CSU Denver ... 2012, MyRounding is based in Denver, Colo. The cloud-based, ...
(Date:9/2/2014)... 02, 2014 Eric Jimenez and Leah ... , a revolutionary makeup application device. Designed to improve ... innovation in the palm of women’s hands to help ... to Color Me’s success lies in its patented technology. ... rate of 15,000 pulses per minute, the device applies ...
Breaking Medicine News(10 mins):Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MyRounding Selected for Digital Health Venture Showcase Finals Top Three Startups Awarded $50,000 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3
... , SCHAUMBURG, Ill., July 29 The American ... on Cancer (IARC) for its re-categorization of indoor tanning devices ... the highest cancer risk category afforded by this international agency, ... , , "The American Academy of ...
... advisory panel outlines priorities for a fall flu shot rollout ... are pregnant, children six months and older, and health ... swine flu vaccine arrives this fall, a U.S. government advisory ... first-line recipients are parents and caregivers of infants; non-elderly adults ...
... , , , ... ESRX ) announced second quarter net income from continuing operations ... items in the quarter, primarily related to the previously announced acquisition ... was $0.88, up 16% from $0.76 for the same period last ...
... , , ARMONK, N.Y., July 29 ... that St. Elizabeth Healthcare is connecting hospitals, clinics and ... records to improve patient care and lower costs. , , ... Today, only 1.5 percent of U.S. hospital systems have a comprehensive ...
... ARLINGTON, Va., July 29 In response to ... and services (durable medical equipment) and about the Medicare competitive ... has developed a "Myth vs. Reality" list to set the ... Association for Homecare urges members of the media to consider ...
... cancer patients, experts say , WEDNESDAY, July 29 (HealthDay News) ... genomes has been completed by U.S. scientists, who said this ... of blood cancer and advance efforts to develop new therapies. ... samples was conducted as part of the Multiple Myeloma Genomics ...
Cached Medicine News:Health News:American Academy of Dermatology Commends Reclassification of Tanning Beds as Carcinogenic 2Health News:American Academy of Dermatology Commends Reclassification of Tanning Beds as Carcinogenic 3Health News:Pregnant Women, Health-Care Workers Top Swine Flu Vaccine Candidates 2Health News:Express Scripts Reports Strong Second Quarter Earnings 2Health News:Express Scripts Reports Strong Second Quarter Earnings 3Health News:Express Scripts Reports Strong Second Quarter Earnings 4Health News:Express Scripts Reports Strong Second Quarter Earnings 5Health News:Express Scripts Reports Strong Second Quarter Earnings 6Health News:Express Scripts Reports Strong Second Quarter Earnings 7Health News:Express Scripts Reports Strong Second Quarter Earnings 8Health News:Express Scripts Reports Strong Second Quarter Earnings 9Health News:Express Scripts Reports Strong Second Quarter Earnings 10Health News:Express Scripts Reports Strong Second Quarter Earnings 11Health News:Express Scripts Reports Strong Second Quarter Earnings 12Health News:Express Scripts Reports Strong Second Quarter Earnings 13Health News:Express Scripts Reports Strong Second Quarter Earnings 14Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 2Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 3Health News:American Association for Homecare Sets the Record Straight About Recent Home Medical Equipment Issues in the News 2Health News:American Association for Homecare Sets the Record Straight About Recent Home Medical Equipment Issues in the News 3Health News:Multiple Myeloma Genome Unlocked 2
(Date:9/2/2014)... Israel , September 2, 2014 ... (TASE, NASDAQ: EMITF ) announced today following ... Medical Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M), a subsidiary ... on a fully diluted basis, announced that on September ... holds approximately 30.8% of the voting power ("Gamida Cell") ...
(Date:9/2/2014)... Bluegrass Vascular Technologies (BVT), ... lifesaving devices and methods for vascular access procedures, ... Niederauer , a seasoned senior medical device executive, ... of Series A financing, BVT is focused on ... Catheter System, a proprietary system that allows physicians ...
(Date:9/2/2014)... SOUTH SAN FRANCISCO, Calif. , Sept. 2, 2014 /PRNewswire/ ... announced that Bonnie H. Anderson , president and chief ... at the Morgan Stanley Global Healthcare Unplugged Conference 2014 on ... New York . The live audio ... website at http://investor.veracyte.com . Please connect to the website ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 3Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... Stereotaxis, Inc. (Nasdaq: STXS ) announced today ... million credit facility, which includes a $30 million revolving facility ... term loan that matures on December 31, 2013.  The new ... Company,s previous facility that was scheduled to mature in March ...
... TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 Regeneron ... HealthCare today announced positive top-line results for VEGF Trap-Eye ... led by Regeneron, the first of two Phase 3 ... retinal vein occlusion (CRVO).  In this trial, 56.1 percent ...
Cached Medicine Technology:Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 7Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 8Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 9
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
Medicine Products: